Research company Active Biotech announces that the first three patients under the updated study protocol have completed six weeks of safety evaluation in the phase Ib/II TasqForce study of tasquinimod for myelofibrosis.
Another three patients will now be recruited to confirm safety and tolerability and establish the dosage ahead of phase II. According to the company, an observed serious adverse event does not alter the overall safety assessment.
The study is being conducted with Oncode and Hovon.
“The encouraging safety and tolerability results in the first cohort support continued clinical evaluation of tasquinimod in myelofibrosis. I look forward to the continued development of the study and to further clinical data being generated,” says Dr Martina Crysandt, deputy study investigator.
